Repligen Co. (NASDAQ:RGEN) Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA cut its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 43.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,858 shares of the biotechnology company’s stock after selling 23,871 shares during the quarter. Primecap Management Co. CA owned about 0.06% of Repligen worth $4,442,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of RGEN. Signaturefd LLC boosted its holdings in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 124 shares during the last quarter. Polen Capital Management LLC boosted its stake in Repligen by 14.6% during the fourth quarter. Polen Capital Management LLC now owns 40,556 shares of the biotechnology company’s stock worth $5,838,000 after buying an additional 5,173 shares during the last quarter. CBIZ Investment Advisory Services LLC purchased a new stake in Repligen in the 4th quarter valued at $58,000. Natixis Advisors LLC increased its stake in shares of Repligen by 31.8% in the 4th quarter. Natixis Advisors LLC now owns 44,317 shares of the biotechnology company’s stock worth $6,379,000 after acquiring an additional 10,692 shares during the last quarter. Finally, Swiss National Bank raised its holdings in shares of Repligen by 0.9% during the 4th quarter. Swiss National Bank now owns 104,700 shares of the biotechnology company’s stock worth $15,071,000 after acquiring an additional 900 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Activity

In other news, Director Margaret Pax acquired 250 shares of Repligen stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.20% of the company’s stock.

Repligen Price Performance

Shares of RGEN opened at $144.88 on Thursday. The company has a market cap of $8.12 billion, a P/E ratio of -284.08, a PEG ratio of 4.54 and a beta of 0.95. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $200.23. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm’s 50 day moving average price is $156.78 and its 200 day moving average price is $148.46.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. On average, research analysts forecast that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RGEN has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. JPMorgan Chase & Co. raised their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Royal Bank of Canada upped their price objective on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 target price for the company. Finally, StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $178.64.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.